wildpixel/iStock via Getty Images C4 Therapeutics ( CCCC ) on Thursday announced a new collaboration with its long-standing partner Roche ( RHHBY ) ( RHHBF ) to develop a new class of cancer drugs called degrader-antibody conjugates (DACs). Under the partnership, the companies will combine antibody-drug conjugation (ADC) with targeted protein degradation (TPD) using C4’s ( CCCC ) TORPEDO platform,...
wildpixel/iStock via Getty Images C4 Therapeutics ( CCCC ) on Thursday announced a new collaboration with its long-standing partner Roche ( RHHBY ) ( RHHBF ) to develop a new class of cancer drugs called degrader-antibody conjugates (DACs). Under the partnership, the companies will combine antibody-drug conjugation (ADC) with targeted protein degradation (TPD) using C4’s ( CCCC ) TORPEDO platform, advancing two DAC-based programs against undisclosed oncology targets. Watertown, Massachusetts-based C4 Therapeutics ( CCCC ) is eligible to receive $20M from Roche ( RHHBY ) for the two programs, with an additional payment due if the Swiss drugmaker exercises its option for a third program. In addition to tiered royalties on future sales, the company is entitled to more than $1B in milestone payments from the collaboration, subject to the achievement of certain R&D, regulatory, and commercial targets. C4 Therapeutics ( CCCC ) first signed a licensing deal with Roche ( RHHBF ) in 2016. “For the past decade, C4T and Roche have worked together to drive research in targeted protein degradation and to establish this modality as a new way to treat cancer,” CEO Andrew Hirsch remarked. More on C4 Therapeutics, Roche Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both) Roche Holding AG (RHHBY) Discusses Phase III Study Results and Updates on Immunology Kidney Pipeline - Slideshow Roche Falters In A Key Breast Cancer Readout TrumpRx adds medicines from AbbVie and Roche’s Genentech: report Teva gains approval of biosimilar of Amgen's Prolia
The chip company’s stellar streak is under threat early Thursday as the shares pointed 1.7% lower in premarket trading. The move lower also appears to be tied to broader market weakness—and creeping doubts about the U.S.-Iran cease-fire agreement. Intel announced it was joining Tesla and SpaceX’s Terafab project—Elon Musk’s semiconductor production plan, which he has described as the “most epic ch...
The chip company’s stellar streak is under threat early Thursday as the shares pointed 1.7% lower in premarket trading. The move lower also appears to be tied to broader market weakness—and creeping doubts about the U.S.-Iran cease-fire agreement. Intel announced it was joining Tesla and SpaceX’s Terafab project—Elon Musk’s semiconductor production plan, which he has described as the “most epic chip building exercise in history.”
Spire Global ( SPIR ) on Thursday said it has agreed to a private placement of 5 million Class A shares at $14 per share, expected to generate approximately $70 million in gross proceeds. The transaction, expected to close on April 10, will be used for working capital and general corporate purposes, including expanding sales and marketing, deploying technology for radio frequency geolocation and w...
Spire Global ( SPIR ) on Thursday said it has agreed to a private placement of 5 million Class A shares at $14 per share, expected to generate approximately $70 million in gross proceeds. The transaction, expected to close on April 10, will be used for working capital and general corporate purposes, including expanding sales and marketing, deploying technology for radio frequency geolocation and weather data, and enhancing cybersecurity for sovereign data operations. The shares have not been registered under the Securities Act and will be subject to resale restrictions. SPIR -24.43% premarket to $15.49. Source: Press Release More on Spire Spire Global: A High-Growth Space Data Platform At An Inflection Point Spire Global, Inc. (SPIR) Q4 2025 Earnings Call Transcript Spire Global, Inc. 2025 Q4 - Results - Earnings Call Presentation Industrial stocks hit fresh highs as ceasefire rally lifts infrastructure names Spire Global targets 50% core revenue growth for 2026 as RFGL capacity expands 15x
Neogen (NEOG) delivered earnings and revenue surprises of +125.00% and +3.30%, respectively, for the quarter ended February 2026. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) delivered earnings and revenue surprises of +125.00% and +3.30%, respectively, for the quarter ended February 2026. Do the numbers hold clues to what lies ahead for the stock?
Artificial intelligence (AI) stocks were major winners for investors over the past few years -- but in recent weeks, these exciting players no longer led gains. In fact, they've been weighing on the S&P 500 's performance. Why the change? Several uncertainties -- from turmoil in Iran to the U.S. economic backdrop -- have hurt investors' appetite for growth stocks, including AI players. Growth stoc...
Artificial intelligence (AI) stocks were major winners for investors over the past few years -- but in recent weeks, these exciting players no longer led gains. In fact, they've been weighing on the S&P 500 's performance. Why the change? Several uncertainties -- from turmoil in Iran to the U.S. economic backdrop -- have hurt investors' appetite for growth stocks, including AI players. Growth stocks generally thrive when the economy is doing well, so any threat to stability or growth isn't good news for them. This has led to high volatility in the stock market, and the trend may not be over -- though the U.S. announced a two-week ceasefire in Iran to allow for negotiations, it's still too soon to say when the conflict will end. So you may still be scared of volatility and hesitant to invest in AI players. But the good news is this one AI stock in particular is built for uncertain markets. Continue reading
(RTTNews) - Medicenna Therapeutics Corp. (MDNAF.PK), Thursday announced the appointment of Dr. Nageatte Ibrahim as Chief Medical Officer of the company.
(RTTNews) - Medicenna Therapeutics Corp. (MDNAF.PK), Thursday announced the appointment of Dr. Nageatte Ibrahim as Chief Medical Officer of the company.
Big Tech will have to do a lot of convincing this coming earnings season that aggressive capital expenditures to build AI infrastructure will deliver strong returns.
Big Tech will have to do a lot of convincing this coming earnings season that aggressive capital expenditures to build AI infrastructure will deliver strong returns.
Ashi Sae Yang/iStock via Getty Images Not all commodity funds are built the same. Right now, that matters. The differences are doing more than showing up in performance. They are telling a story investors need to understand. A rare and powerful market dynamic is unfolding. Energy markets have been turned upside down by a historic supply disruption. A conflict-driven shutdown of Gulf oil production...
Ashi Sae Yang/iStock via Getty Images Not all commodity funds are built the same. Right now, that matters. The differences are doing more than showing up in performance. They are telling a story investors need to understand. A rare and powerful market dynamic is unfolding. Energy markets have been turned upside down by a historic supply disruption. A conflict-driven shutdown of Gulf oil production, estimated at nearly 9 million barrels per day, has driven crude oil futures into steep backwardation. As of April 7, front-month WTI is trading near $110 per barrel, while prices for delivery in late 2026 slope down toward the mid-$70s. This creates a powerful positive roll yield tailwind. In Understanding the Components of Commodity Futures Returns , we looked at how spot price movement, collateral yield and roll yield drive commodity returns. We’re seeing that framework in action today, with roll yield now taking center stage. When futures curves are backwardated, investors rolling expiring contracts sell high and buy low, earning a positive spread. History shows how consequential this can be. During the structurally backwardated energy markets of the 1970s and early 1980s, S&P Goldman Sachs Commodity Index (S&P GSCI) roll yield averaged 4.77% and 2.41% annualized, respectively. In contrast, when energy contango dominated the 2000s, that same figure turned sharply negative, to -8.25%. The current environment is squarely in the first camp—and it is historically rare. CMCI: Built for the Long Game The UBS Constant Maturity Commodity Index (“CMCI Index”), the benchmark behind both the VanEck CMCI Commodity Strategy ETF ( CMCI ) and CM Commodity Index Fund , was designed with a specific, long-term view: commodity futures markets are in contango most of the time, and when in contango, front-month concentration is the most expensive place for investors to sit. The index addresses this by spreading exposure across the futures curve, spreading positions three months to three ye...